BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20067552)

  • 1. alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.
    Hu R; Aplin AE
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):201-9. PubMed ID: 20067552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.
    Lin DI; Barbash O; Kumar KG; Weber JD; Harper JW; Klein-Szanto AJ; Rustgi A; Fuchs SY; Diehl JA
    Mol Cell; 2006 Nov; 24(3):355-66. PubMed ID: 17081987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
    Bhatt KV; Hu R; Spofford LS; Aplin AE
    Oncogene; 2007 Feb; 26(7):1056-66. PubMed ID: 16924241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCF(Fbx4/alphaB-crystallin) E3 ligase: when one is not enough.
    Barbash O; Diehl JA
    Cell Cycle; 2008 Oct; 7(19):2983-6. PubMed ID: 18818515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation.
    Barbash O; Egan E; Pontano LL; Kosak J; Diehl JA
    Oncogene; 2009 Dec; 28(49):4317-25. PubMed ID: 19767775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
    Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
    Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The small heat-shock protein alpha B-crystallin promotes FBX4-dependent ubiquitination.
    den Engelsman J; Keijsers V; de Jong WW; Boelens WC
    J Biol Chem; 2003 Feb; 278(7):4699-704. PubMed ID: 12468532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FBX4 mediates rapid cyclin D1 proteolysis upon DNA damage in immortalized esophageal epithelial cells.
    Liu J; Yang H; Cheung PY; Tsao SW; Lv L; Cheung ALM
    Biochem Biophys Res Commun; 2021 May; 554():76-82. PubMed ID: 33784509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock factor 1 deficiency via its downstream target gene alphaB-crystallin (Hspb5) impairs p53 degradation.
    Jin X; Moskophidis D; Hu Y; Phillips A; Mivechi NF
    J Cell Biochem; 2009 Jun; 107(3):504-15. PubMed ID: 19343786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
    Gassenmaier M; Rentschler M; Fehrenbacher B; Eigentler TK; Ikenberg K; Kosnopfel C; Sinnberg T; Niessner H; Bösmüller H; Wagner NB; Schaller M; Garbe C; Röcken M
    Am J Pathol; 2020 Oct; 190(10):2155-2164. PubMed ID: 32679231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXD3 regulates migration properties and Rnd3 expression in melanoma cells.
    Katiyar P; Aplin AE
    Mol Cancer Res; 2011 May; 9(5):545-52. PubMed ID: 21478267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
    Abel EV; Aplin AE
    Cancer Res; 2010 Apr; 70(7):2891-900. PubMed ID: 20332228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
    Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM
    Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.
    Spofford LS; Abel EV; Boisvert-Adamo K; Aplin AE
    J Biol Chem; 2006 Sep; 281(35):25644-51. PubMed ID: 16815849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
    Mirza AM; Gysin S; Malek N; Nakayama K; Roberts JM; McMahon M
    Mol Cell Biol; 2004 Dec; 24(24):10868-81. PubMed ID: 15572689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
    Smalley KS; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
    Mol Cancer Ther; 2008 Sep; 7(9):2876-83. PubMed ID: 18790768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.